跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03414684
NCT03414684已完成2 期

A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer

Dana-Farber Cancer Institute20 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2018年1月30日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
78
试验地点
20
主要终点
Progression-free Survival
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.

The interventions involved in this study are:

  • Carboplatin
  • Nivolumab

详细描述

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved nivolumab for your specific disease but it has been approved for other uses. The FDA has approved carboplatin as a treatment option for your disease.

The purpose of this research study is to determine how well carboplatin, by itself, or together with nivolumab, works in treating breast cancer that has spread to other parts of the body. Nivolumab is a recently discovered human monoclonal antibody. An antibody is a type of protein that your immune system (the system that defends your body against potentially harmful particles) uses to find and destroy foreign molecules (particles not typically found in your body, such as bacteria and viruses). Scientists can now make antibodies in the laboratory and produce them for the treatment of many different diseases.

Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cell. Nivolumab has been shown in research studies to prevent PD-1 from shutting down the immune system, thus allowing it to recognize and help your body destroy the cancer cells. You are being asked to participate in this study because triple-negative breast cancer has shown elevated rates of PD-L1 expression.

Nivolumab has been used in other research studies and information from those research studies suggests that nivolumab may help shrink or stabilize your triple negative breast cancer in this study

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Participants must have histologically or cytologically confirmed invasive breast cancer, with unresectable locally advanced or metastatic disease. Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation.
  • •Estrogen-receptor and progesterone-receptor expression both ≤ 1% by immunohistochemistry (IHC), and HER2-negative status as determined by the current ASCO/CAP guidelines. If a patient has more than one histological result, the most recent sample will be considered for inclusion.
  • •Participants must have PD-L1 status available at the time of registration. Standard local testing with any PD-L1 antibody that has been validated in a CLIA-certified environment will be acceptable for including patients on trial.. Primary or metastatic samples may be tested for PD-L1 status.
  • •Participants must have measurable or evaluable disease by RECIST version 1.
  • •Participants must agree to undergo a research biopsy, if tumor is safely accessible, at baseline. Previously collected archival tissue will also be obtained on all participants. For participants for whom newly-obtained samples cannot be provided (e.g. inaccessible or participant safety concern) the archival tissue alone will be acceptable. Tissue needs to be located and availability confirmed at time of registration (See Section 9 for more details). Participants must agree to a mandatory repeat biopsy 3-6 weeks after starting treatment, if tumor is safely accessible. For patients randomized to carboplatin alone who decide to crossover to nivolumab and nab-paclitaxel at time of progression, a mandatory biopsy will be required if tumor is safely accessible prior to initiating crossover treatment; participants must also agree to undergo this biopsy, if applicable.
  • •Prior chemotherapy: Participants must have received 0 prior chemotherapeutic regimens for metastatic breast cancer. Prior platinum in the neo/adjuvant setting is permissible, if at least 6 months elapsed since the end of adjuvant systemic therapy to the development of metastatic disease. All toxicities related to prior chemotherapy must have resolved to CTCAE v4.0 grade 1 or lower, unless otherwise specified.
  • •Prior biologic therapy: Prior poly-ADP ribose polymerase (PARP) inhibitors are not allowed in the metastatic setting. Prior PARP inhibitors in the neo/adjuvant setting are permissible, if at least 6 months elapsed since the end of adjuvant systemic therapy to the development of metastatic disease. All toxicities related to prior biologic therapy must have resolved to CTCAE v4.0 grade 1 or lower, unless otherwise specified.
  • •Prior radiation therapy: Patients may have received prior radiation therapy. Radiation therapy must be completed at least 14 days prior to registration, and all toxicities related to prior radiation therapy must have resolved to CTCAE v4.0 grade 1 or lower, unless otherwise specified in 3.1.
  • •Patients may not have had >25% of their bone marrow radiated.
  • •The subject is ≥18 years old.
  • •ECOG performance status ≤1 (Karnofsky >60%, see Appendix A).
  • •Participants must have normal organ and marrow function as defined below:
  • •Absolute neutrophil count ≥1,500/mcL
  • •Platelets ≥100,000/mcL
  • •Hemoglobin ≥ 9.0 g/dl
  • •Total bilirubin ≤1.5 × institutional upper limit of normal (ULN) (or ≤2.0 x ULN in patients with documented Gilbert's Syndrome)
  • •AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN or
  • •≤5 × institutional ULN for participants with documented liver metastases
  • •Serum creatinine ≤1.5 × institutional ULN OR creatinine clearance ≥ 45 mL/min/ 1.73m2 for participants with creatinine levels above institutional ULN.
  • •Supportive care (e.g. transfusion of red blood cells) is allowed to meet eligibility criteria.
  • •Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to registration.
  • •Childbearing potential is defined as: participants who have not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus).
  • •Women of childbearing potential (WOCBP) must agree to use an adequate method of contraception. Contraception is required starting with the first dose of study medication through 150 days (5 months) after the last dose of study medication. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, established and proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
  • •Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment with nivolumab and 7 months after the last dose of study treatment (i.e., 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo approximately five half-lives.)
  • •Participants on bisphosphonates or RANK ligand inhibitors may continue receiving therapy during study treatment.
  • •The participant must be capable of understanding and complying with the protocol and willing to sign a written informed consent document

排除标准

  • •Concurrent administration of any other anti-cancer therapy during the course of this study (bisphosphonates and RANK ligand inhibitors are allowed).
  • •Prior hypersensitivity to platinum chemotherapy or to any of the excipients of platinum or nivolumab therapy.
  • •Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including pembrolizumab, ipilimumab, and any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
  • •Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms. Participants with a history of treated central nervous system (CNS) metastases are eligible. Treated brain metastases are defined as those without ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging or CT scan) completed during screening. Any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for ≥7 days prior to registration. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery, surgery or a combination as deemed appropriate by the treating physician. Radiation therapy must be completed at least 7 days prior to registration
  • •Major surgery within 2 weeks prior to registration. Patients must have recovered from any effects of any major surgery.
  • •Uncontrolled, significant intercurrent or recent illness including, but not limited to, ongoing or active infection, uncontrolled non-malignant systemic disease, uncontrolled seizures, or psychiatric illness/social situation that would limit compliance with study requirements in the opinion of the treating investigator.
  • •Participant has a medical condition that requires chronic systemic steroid therapy (> 10 mg of prednisone daily or equivalent) or any other form of immunosuppressive medication (including disease modifying agents) and has required such therapy in the last 2 years. Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy.
  • •Participant has documented history of autoimmune disease or syndrome that currently requires systemic steroids or immunosuppressive agents.
  • •History or evidence of active, non-infectious pneumonitis or interstitial lung disease.
  • •Individuals with a history of a second malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers that have been diagnosed and treated within the past 3 years are eligible: cervical/prostate carcinoma in situ, superficial bladder cancer, non-melanoma cancer of the skin. Patients with other cancers diagnosed within the past 3 years and felt to be at low risk of recurrence should be discussed with the study sponsor to determine eligibility.
  • •Participant is known to be positive for the human immunodeficiency virus (HIV), HepBsAg, or HCV RNA. HIV-positive participants are ineligible because of the potential for pharmacokinetic interactions of combination antiretroviral therapy with study drugs. In addition, these participants are at increased risk of fatal infections when treated with marrow-suppressive therapy.
  • •The participant has received a live vaccine within 28 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. The use of the inactivated seasonal influenza vaccine is allowed.
  • •Women who are pregnant or breastfeeding or adults of reproductive potential not employing an adequate method of contraception.
  • •Childbearing potential is defined as: participants who have not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause) and have not undergone surgical sterilization (removal of ovaries and/or uterus)

研究组 & 干预措施

Carboplatin + Nivolumab

Experimental
  • Nivolumab is administered every three weeks intravenously
  • Nivolumab dosage is 360mg
  • Carboplatin is administered every three weeks intravenously
  • Carboplatin dosage is pre-determined by the PI

干预措施: Carboplatin (Drug)

Carboplatin + Nivolumab

Experimental
  • Nivolumab is administered every three weeks intravenously
  • Nivolumab dosage is 360mg
  • Carboplatin is administered every three weeks intravenously
  • Carboplatin dosage is pre-determined by the PI

干预措施: Nivolumab (Drug)

Carboplatin

Active Comparator
  • Carboplatin is administered every three weeks intravenously
  • Carboplatin dosage is pre-determined by the PI

干预措施: Carboplatin (Drug)

结局指标

主要结局

Progression-free Survival

时间窗: Assessed from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3.5 years

Defined as the time from randomization to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation

次要结局

  • Progression-free Survival Among PD-L1-positive Patients(Assessed from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3.5 years)
  • Duration of Response(Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) to the time of first progression, up to 2.75 years)
  • Time to Objective Response(Assessed from randomization to the time of first response, up to 3.5 years)
  • Duration of Response Among PD-L1-positive Patients(Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) to the time of first progression, up to 2.75 years)
  • Second-course Progression-free Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab(Assessed from the start of crossover therapy to the date of first documented progression on crossover therapy or the date of death from any cause, whichever came first, up to 2.8 years)
  • Second-course Objective Response Rate by RECIST 1.1 Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab(Assessed from the start of crossover treatment until disease progression, intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 2.8 years)
  • Clinical Benefit Rate(Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years)
  • Objective Response Rate by irRC Among PD-L1-positive Patients(Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years)
  • Time to Objective Response Among PD-L1-positive Patients(Assessed from randomization to the time of first response, up to 3.5 years)
  • Objective Response Rate by RECIST 1.1 Among PD-L1-positive Patients(Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years)
  • Progression-free Survival Among BRCA-mutant Patients(Assessed from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3.5 years)
  • Clinical Benefit Rate Among BRCA-mutant Patients(Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years)
  • Objective Response Rate by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1(Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years)
  • Objective Response Rate by Immune-Related Response Criteria (irRC)(Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years)
  • Overall Survival(Assessed from date of randomization until the date of death from any cause, up to 3.5 years)
  • Overall Survival Among PD-L1-positive Patients(Assessed from date of randomization until the date of death from any cause, up to 3.5 years)
  • Second-course Objective Response Rate by irRC Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab(Assessed from the start of crossover treatment until disease progression, intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 2.8 years)
  • Second-course Overall Survival Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab(Assessed from the start of crossover therapy until the date of death from any cause, up to 2.8 years)
  • Time to Objective Response Among BRCA-mutant Patients(Assessed from randomization to the time of first response, up to 3.5 years)
  • Clinical Benefit Rate Among PD-L1-positive Patients(Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years)
  • Second-course Duration of Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab(Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) on crossover therapy to the time of first progression on crossover therapy, up to 2.5 years)
  • Objective Response Rate by irRC Among BRCA-mutant Patients(Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years)
  • Overall Survival Among BRCA-mutant Patients(From date of randomization until the date of death from any cause, assessed up to 3.5 years)
  • Second-course Clinical Benefit Rate Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab(Assessed from the start of crossover treatment until disease progression, intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 2.8 years)
  • Second-course Time to Objective Response Among Patients Who Crossed Over to Nab-paclitaxel Plus Nivolumab(Assessed from the start of crossover therapy to the time of first response on crossover therapy, up to 2.8 years)
  • Objective Response Rate by RECIST 1.1 Among BRCA-mutant Patients(Assessed from the start of treatment until disease progression, complete response (after at least 24 weeks of treatment), intercurrent illness, unacceptable toxicity, noncompliance/withdrawal, or general/specific worsening of condition, up to 3.5 years)
  • Duration of Response Among BRCA-mutant Patients(Assessed from the time measurement criteria are met for CR or PR by RECIST 1.1 (whichever is first recorded) to the time of first progression, up to 3.5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sara Tolaney, MD

Principal Investigator

Dana-Farber Cancer Institute

研究点 (20)

Loading locations...

相似试验

已完成
2 期
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung CancerNon Squamous Non Small Cell Lung Cancer
NCT01829113SCRI Development Innovations, LLC155
已完成
不适用
Randomized phase II trial comparing carboplatin plus irinotecan with carboplatin plus amrubicine for extensive disease small-cell lung cancerSmall-cell lung cancer
JPRN-UMIN000008970orth-Japan lung cancer group70
已完成
2 期
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Recurrent Adult Acute Myeloid Leukemia
NCT00634244National Cancer Institute (NCI)92
进行中（未招募）
2 期
A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
ACTRN12616000958482Australasian Gastro-Intestinal Trials Group (AGITG)60
已完成
2 期
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast CancerEstrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-negative Breast Cancer
NCT01818063Sidney Kimmel Cancer Center at Thomas Jefferson University9